On November 5, the 7th China International Import Expo (hereinafter referred to as the Expo) kicked off. Medtronic, a global medical technology enterprise, focused on the four major medical fields of heart and blood vessel, medical surgery, neuroscience and diabetes, with the theme of "making progress, being extraordinary and common", and brought seven debut products. Nearly 20 star products representing the spillover effect of Expo will also return to the Expo.
7 debut products showcased at the CIIE
The CIIE is an important platform for enterprises to showcase cutting-edge technological achievements and promote diverse exchanges. Working hand in hand with Jinbo for seven years, Medtronic has brought nearly 400 innovative products and therapies, while maintaining its tradition of introducing new products every year. This year, Medtronic exhibited a total of 7 debut products, including 1 global debut, 4 Asia Pacific debuts, and 2 Chinese debut products. Among them, Medtronic's new generation of transcatheter aortic valve replacement system, Evolution FX+, which is used to treat aortic valve stenosis, is the world's first exhibition. The product features an innovative "valve frame large window" design, providing greater space for future coronary intervention catheterization operations and dedicated to providing lifelong management for patients with active aortic valve stenosis; The four Asia Pacific debut exhibits focus on neural regulation, pain management, and the fields of heart and blood vessels, meeting clinical treatment needs through innovative technologies, including the latest generation of intelligent perceptible and rechargeable brain pacemaker Perception RC, implantable drug infusion pump SynchroMed III for treating cancer pain, other chronic pain, and spasms, portable VitalFlow ECMO system for life support in emergency and critical patients, and Penditure left atrial appendage closure system designed specifically for left atrial appendage management and prevention of surgical treatment of cardiogenic stroke; The two first products showcased in China are the Nitro CryoConsole cryoablation device for cardiac atrial fibrillation cryoablation surgery, and the Tri Ad 2.0 Adams tricuspid valve forming ring with a "flexible" and "semi-rigid" structure for cardiac surgery.
During the entire CIIE period, Medtronic will also hold more than ten booth activities, from the release of new products and technologies, disease and health science popularization and free clinics, to the "Angel Loves Science" public welfare project, etc. While showcasing the extraordinary beauty of medical technology, Medtronic will convey its commitment to accelerating innovation and empowering the local medical industry with new quality productivity, and jointly building a commitment to life and health.
This year is also the seventh year that Medtronic has fully participated in the China International Import Expo. The Expo is an important platform for sharing opportunities in the Chinese market and showcasing global innovative medical technology, "said Jeff Massa, Chairman and CEO of Medtronic
It is worth mentioning that, thanks to the strong influence of the CIIE, Medtronic has transformed nearly 20 "star exhibits" into "star products", better meeting the diverse and high-quality medical service needs of the local market. Among them, three exhibits that made their debut at last year's CIIE have achieved milestone results. Among them, the EV-ICD vascular implantable cardioversion defibrillator, which is used to prevent sudden cardiac death, underwent its first surgery in May this year through the Boao Pilot Zone in Hainan; The PulseSelect pulsed field ablation system was approved by the National Medical Products Administration in September this year. Thus, Medtronic has become the only multinational enterprise currently offering the "Ice Fire Electric" atrial fibrillation ablation technique in the Chinese market; The StealthStation Flex ENT intraoperative electromagnetic navigation system for otolaryngology has been officially launched in China this year, injecting new vitality into medical practice in the field of otolaryngology.
Among the many "returning" celebrity exhibits, there are also "black technologies". Among them, PillCam small intestine capsule endoscopy can be applied to people over 2 years old. By having patients swallow a capsule and using the built-in camera to record images of the small intestine, it can help doctors diagnose small intestine diseases; The chip intelligent matching platform Signia helps surgeons achieve personalized surgical plans based on tissue differences through intelligent control. In addition, the platform consists of multiple reusable components, and research has shown that it can reduce the generation of medical waste by 40% -70%, helping to achieve the dual carbon goal; The new generation of Medtronic Brain and Regional Oxygen Saturation Monitor PM7100 uses near-infrared light technology to non invasively monitor tissue oxygen saturation (rSO2) in areas such as the patient's head, forehead, chest, and back in medical environments, and continuously reflect the oxygenation status and trends of brain and regional tissues in real time, bringing a new solution for medical monitoring.
CIIE becomes an opportunity to expand localization
Having been deeply rooted in China for 35 years, as one of the first multinational medical technology companies to enter China, Medtronic has one research and development center, two innovation centers, and five major production bases in China. It has built a full value chain layout covering research and development, production, sales, training, after-sales, investment funds, and more. Medtronic has demonstrated its deep connection with the Chinese market in all aspects, from meeting local clinical needs to achieving local manufacturing and research and development.
In 2003, Medtronic was the first to introduce innovative stroke mediation treatment technology into China and launched its first spring coil in 2009. In order to meet more diversified local needs, Medtronic's first localized product for neurointerventional therapy, the Meianxin mechanical detachable spring coil, will be officially launched in August 2023. The product has up to 83 models, covering 4 fine proportioned soft gradients, and is suitable for various tumor types, providing clinical doctors with rich embolization solutions.
In terms of blood glucose management, the Meiling Advanced Intelligent Blood Glucose Management Workstation, born in the Medtronic China R&D Center, integrates the blood glucose monitoring data of hospitalized patients with insulin infusion information through advanced information technology, and displays it in real-time on the blood glucose management workstation, mobile ward round terminals, and patient education screens. Doctors and nurses can monitor patients' blood sugar fluctuations at any time, achieve "monitoring and adjusting sugar levels", optimize treatment plans, and ensure timely treatment for patients.
As two representative practical achievements of Medtronic empowering local medical new quality productivity, Medtronic Lingang Medical Technology Industry Base and Medtronic Kanghui Changzhou Science and Technology Park shine as the "twin stars" of Medtronic's local "quality" manufacturing at the 7th CIIE China Pavilion. Medtronic Lingang Medical Technology Industrial Base focuses on heart disease management, providing comprehensive solutions including diagnosis, treatment, and disease management for Chinese patients and clinical practice; Medtronic Kanghui Changzhou Science and Technology Park, which focuses on orthopedics and neurosurgery, has launched locally manufactured products such as Mazor XC spinal surgery navigation system, Engine Nav spinal surgery navigation system, NIM Eclipse intraoperative nerve monitoring system, etc. around the AiBLE innovative solution, empowering the development of new quality productivity in the industry.
We have been walking together for 7 years, and every year we come to CIIE, we have new experiences and gains. The strong spillover effect of the CIIE platform has enabled our innovative medical technology to move from the exhibition booth to clinical practice and approach patients, "said Gu Yushao, Senior Vice President and President of Greater China at Medtronic." In the 35 years since entering China, we have deeply integrated and firmly strengthened the construction of the local value chain. At the same time, we look forward to working with partners from all walks of life to achieve great development and showcase great achievements in promoting the deep integration of technology innovation and medical industry, helping China's new quality productivity to go global, and serving global patients
Wen/Zhang Xiulan